| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Henan Lingrui Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥21.57 |
| 52 Week High | CN¥27.26 |
| 52 Week Low | CN¥15.66 |
| Beta | 0.33 |
| 11 Month Change | -12.95% |
| 3 Month Change | 3.21% |
| 1 Year Change | 34.98% |
| 33 Year Change | 96.45% |
| 5 Year Change | 107.20% |
| Change since IPO | 159.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| 600285 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -10.9% | -1.9% | -1.2% |
| 1Y | 35.0% | -5.0% | 3.1% |
Return vs Industry: 600285 exceeded the CN Pharmaceuticals industry which returned -4.9% over the past year.
Return vs Market: 600285 exceeded the CN Market which returned 5.7% over the past year.
Price Volatility
| 600285 volatility | |
|---|---|
| 600285 Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in CN Market | 12.0% |
| 10% least volatile stocks in CN Market | 5.3% |
Stable Share Price: 600285 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600285's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 2,530 | Wei Xiong | www.lingrui.com |
Henan Lingrui Pharmaceutical Co., Ltd. produces and sells medicines in China. The company offers its products in ten dosage forms, such as adhesive plasters, tablets, capsules, granules, tinctures, etc. covering various product varieties. Its products include Tongluoqutong plasters, Peiyuantongnao capsules, Danlutongdu tablets, stomachache free tablets, Shenqi Hypoglycemic capsules, and others.
Henan Lingrui Pharmaceutical Co., Ltd. Fundamentals Summary
| 600285 fundamental statistics | |
|---|---|
| Market cap | CN¥12.15b |
| Earnings (TTM) | CN¥675.80m |
| Revenue (TTM) | CN¥3.56b |
18.0x
P/E Ratio3.4x
P/S RatioIs 600285 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600285 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.56b |
| Cost of Revenue | CN¥942.20m |
| Gross Profit | CN¥2.62b |
| Other Expenses | CN¥1.95b |
| Earnings | CN¥675.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.20 |
| Gross Margin | 73.56% |
| Net Profit Margin | 18.96% |
| Debt/Equity Ratio | 0.5% |
How did 600285 perform over the long term?
See historical performance and comparison